Systematic Financial Management LP decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 16.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 91,794 shares of the medical research company’s stock after selling 17,998 shares during the period. Systematic Financial Management LP’s holdings in Amgen were worth $13,966,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Cue Financial Group Inc. raised its stake in shares of Amgen by 24.7% in the first quarter. Cue Financial Group Inc. now owns 6,922 shares of the medical research company’s stock worth $1,038,000 after buying an additional 1,370 shares in the last quarter. Jacobs & Co. CA raised its stake in Amgen by 1.0% in the first quarter. Jacobs & Co. CA now owns 35,513 shares of the medical research company’s stock valued at $5,324,000 after buying an additional 356 shares during the period. Koshinski Asset Management Inc. raised its stake in Amgen by 2.4% in the first quarter. Koshinski Asset Management Inc. now owns 5,026 shares of the medical research company’s stock valued at $754,000 after buying an additional 120 shares during the period. Campbell Newman Asset Management Inc. raised its stake in Amgen by 4.9% in the first quarter. Campbell Newman Asset Management Inc. now owns 77,148 shares of the medical research company’s stock valued at $11,567,000 after buying an additional 3,569 shares during the period. Finally, Berkshire Asset Management LLC PA raised its stake in Amgen by 3.5% in the first quarter. Berkshire Asset Management LLC PA now owns 86,061 shares of the medical research company’s stock valued at $12,903,000 after buying an additional 2,931 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 174.80 on Friday. The company has a 50-day moving average of $172.09 and a 200-day moving average of $160.08. Amgen Inc. has a 52-week low of $130.09 and a 52-week high of $176.85. The stock has a market capitalization of $130.81 billion, a price-to-earnings ratio of 17.89 and a beta of 0.87.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. During the same quarter last year, the business earned $2.57 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post $11.36 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were given a $1.00 dividend. The ex-dividend date was Monday, August 15th. This represents a $4.00 annualized dividend and a dividend yield of 2.29%. Amgen’s dividend payout ratio (DPR) is 40.90%.
AMGN has been the subject of several analyst reports. BMO Capital Markets restated a “buy” rating and issued a $186.00 price objective on shares of Amgen in a research note on Tuesday, July 12th. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $165.78 price objective for the company in a research note on Wednesday, July 27th. Leerink Swann restated a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday, August 1st. Finally, Robert W. Baird restated a “neutral” rating and issued a $157.00 price objective on shares of Amgen in a research note on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $184.56.
In other news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.